# Dupixent (dupilumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dupilumab

> The FDA approved Dupixent (dupilumab), sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), on Feb 2026 for and children aged 6 years and older with AFRS.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Dupixent (dupilumab) |
| Codes | SAR231893, REGN668 |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | and children aged 6 years and older with afrs, with bullous pemphigoid, and adolescents aged 12 years and older with csu, and adolescents aged 12 years and older with chronic spontaneous urticaria, [Lichen Simplex Chronicus](https://sec-api.dev/indications/lichen-simplex-chronicus), [Eosinophilic Esophagitis (EoE)](https://sec-api.dev/indications/eosinophilic-esophagitis-eoe), [Prurigo Nodularis](https://sec-api.dev/indications/prurigo-nodularis), Eosinophilic Gastritis (EoG) |
| Modality | antibody |
| FDA designations | orphan, priority review |

## Timeline

### March 28, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761055 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170328, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### May 26, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761055 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20200526, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### June 18, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761055 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20200618, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### June 14, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761055 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20210614, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### October 20, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761055 SUPPL-31 (Efficacy): submission_status AP, submission_status_date 20211020, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### May 20, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761055 SUPPL-40 (Efficacy): submission_status AP, submission_status_date 20220520, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### June 7, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761055 SUPPL-42 (Efficacy): submission_status AP, submission_status_date 20220607, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### September 28, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761055 SUPPL-44 (Efficacy): submission_status AP, submission_status_date 20220928, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### January 12, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761055 SUPPL-55 (Efficacy): submission_status AP, submission_status_date 20240112, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### January 25, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761055 SUPPL-57 (Efficacy): submission_status AP, submission_status_date 20240125, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### Apr 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2025-02-14, last confirmed 2025-02-14.
- SEC Form 10-K (accession 0001551152-25-000020): "•In April 2024, AbbVie announced positive top-line results from the head-to-head Phase 3b/4 Level-Up trial evaluating Rinvoq compared to dupilumab in adolescent and adult patients with moderate to severe atopic dermatitis." https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm
- SEC Form 10-K (accession 0001551152-25-000020): "•In April 2024, AbbVie announced positive top-line results from its Phase 3 SELECT-GCA trial for Rinvoq in combination with a 26-week steroid taper regimen in patients with giant cell arteritis (GCA) achieved its primary endpoint." https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm

### September 12, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761055 SUPPL-66 (Efficacy): submission_status AP, submission_status_date 20240912, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### September 27, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761055 SUPPL-64 (Efficacy): submission_status AP, submission_status_date 20240927, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### Feb 2025: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-04-29, last confirmed 2025-04-29.
- Press release filed with the SEC (EX-99) (accession 0001804220-25-000020): "In February 2025, the FDA accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent in bullous pemphigoid, with a target action date of June 20, 2025." https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm

### Apr 2025: FDA approval

- Status: completed, approved. Date confidence: month. Indication: and adolescents aged 12 years and older with CSU.
- First seen 2025-08-01, last confirmed 2025-08-01.
- Press release filed with the SEC (EX-99) (accession 0000872589-25-000017): "•In April 2025, the FDA approved Dupixent for the treatment of adults and adolescents aged 12 years and older with CSU who remain symptomatic despite antihistamine treatment." https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm

### April 17, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761055 SUPPL-51 (Efficacy): submission_status AP, submission_status_date 20250417, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### April 18, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact. Indication: and adolescents aged 12 years and older with chronic spontaneous urticaria.
- First seen 2024-11-18, last confirmed 2025-02-05.
- Press release filed with the SEC (EX-99) (accession 0001804220-25-000007): "•The FDA accepted for review the resubmission of an sBLA for Dupixent to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment, with a target action date of April 18, 2025." https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm
- Press release filed with the SEC (EX-99) (accession 0001804220-25-000007): "FDA decision on sBLA for Dupixent in CSU (target action date of April 18, 2025)" https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm
- SEC Form 10-K (accession 0001804220-25-000011): "-FDA decision on sBLA (target action date of April 18, 2025) and EC decision on regulatory submission (first half 2025) for CSU in adults and adolescents" https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-24-260686): "The target action date for the FDA decision is April 18, 2025." https://www.sec.gov/Archives/edgar/data/1121404/000119312524260686/d793925dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001121404-25-000002): "The target action date for the FDA decision is April 18, 2025." https://www.sec.gov/Archives/edgar/data/1121404/000112140425000002/pressreleaseq42024english.htm
- openFDA Drugs@FDA: "BLA761055 SUPPL-51 (Efficacy): submission_status AP, submission_status_date 20250417, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### Jun 2025: FDA approval

- Status: completed, approved. Date confidence: month. Indication: with bullous pemphigoid.
- First seen 2025-08-01, last confirmed 2025-08-01.
- Press release filed with the SEC (EX-99) (accession 0000872589-25-000017): "•In June 2025, the FDA approved Dupixent for the treatment of adults with bullous pemphigoid." https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm

### June 18, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761055 SUPPL-70 (Efficacy): submission_status AP, submission_status_date 20250618, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### June 20, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-04-29, last confirmed 2025-04-29.
- Press release filed with the SEC (EX-99) (accession 0001804220-25-000020): "In February 2025, the FDA accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent in bullous pemphigoid, with a target action date of June 20, 2025." https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm
- SEC Form 10-Q (accession 0001804220-25-000022): "-FDA decision on sBLA (target action date of June 20, 2025) and EC decision on regulatory submission (first half 2026) for bullous pemphigoid" https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/regn-20250331.htm
- openFDA Drugs@FDA: "BLA761055 SUPPL-70 (Efficacy): submission_status AP, submission_status_date 20250618, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### 2H 2025: PDUFA date

- Status: scheduled. Date confidence: half.
- First seen 2025-02-04, last confirmed 2025-02-04.
- Press release filed with the SEC (EX-99) (accession 0001804220-25-000007): "- sBLA acceptance for Dupixent in bullous pemphigoid (first half 2025) and FDA decision on sBLA (second half 2025); regulatory submission in European Union (EU) (first half 2025)" https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm

### Feb 2026: FDA approval

- Status: completed, approved. Date confidence: month. Indication: and children aged 6 years and older with AFRS.
- First seen 2026-04-29, last confirmed 2026-04-29.
- Press release filed with the SEC (EX-99) (accession 0000872589-26-000014): "•In February 2026, the FDA approved Dupixent as the first and only medicine for the treatment of adults and children aged 6 years and older with AFRS." https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm

### February 23, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761055 SUPPL-75 (Efficacy): submission_status AP, submission_status_date 20260223, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### February 23, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05831176 (A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT05831176

### February 28, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-11-18, last confirmed 2026-01-30.
- Press release filed with the SEC (EX-99) (accession 0000872589-26-000004): "Immunology & Inflammation - EC decision on regulatory submission for Dupixent in bullous pemphigoid (first half 2026); FDA decision on sBLA for Dupixent in AFRS (February 2026)" https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/exhibit991q42025.htm
- Press release filed with the SEC (EX-99) (accession 0000872589-26-000004): "Additionally, the U.S. Food and Drug Administration (FDA) accepted for priority review the supplemental Biologics License Application (sBLA) for this indication, which has a target action date in February 2026." https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/exhibit991q42025.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-285701): "Dupixent sBLA accepted for priority review by the US FDA with a target action date of February 28, 2026; if approved, Dupixent would be the first and only medicine indicated specifically for AFRS, which would be its ninth FDA-approved indication" https://www.sec.gov/Archives/edgar/data/1121404/000119312525285701/d895566dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001121404-26-000001): "The US Food and Drug Administration (FDA) accepted for priority review the supplemental biologics license application (sBLA) for Dupixent in AFRS with a target action date of February 28, 2026." https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm
- openFDA Drugs@FDA: "BLA761055 SUPPL-75 (Efficacy): submission_status AP, submission_status_date 20260223, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### April 22, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761055 SUPPL-74 (Efficacy): submission_status AP, submission_status_date 20260422, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22

### May 13, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Colitis Ulcerative.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05731128 (A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-13 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT05731128

### June 8, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Lichen Simplex Chronicus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06687967 (A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-08 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06687967

### June 8, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Lichen Simplex Chronicus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06687980 (A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-08 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06687980

### October 9, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02612454 (Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-09 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT02612454

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02612454 (Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-09 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT02612454

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Prurigo Nodularis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06293053 (A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06293053

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Prurigo Nodularis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06293053 (A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06293053

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Eosinophilic Esophagitis (EoE).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07112378 (A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-19 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07112378

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Eosinophilic Esophagitis (EoE).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07112378 (A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-19 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07112378

### Dec 2028 to Mar 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Wheezing; Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06191315 (Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-12-21 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06191315

### December 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Wheezing; Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06191315 (Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-12-21 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06191315

## Same indication

- [Barzolvolimab](https://sec-api.dev/pdufa/barzolvolimab) (CLDX)
- [Povofortay (povorcitinib)](https://sec-api.dev/pdufa/povorcitinib) (INCY)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)

Calendar months: [October 2027](https://sec-api.dev/fda-calendar/2027-10), [June 2028](https://sec-api.dev/fda-calendar/2028-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dupilumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Dupixent (dupilumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dupilumab

```bibtex
@misc{secapidev_pdufa_dupilumab_20261116,
  title        = {Dupixent (dupilumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dupilumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dupilumab_20261116","title":"Dupixent (dupilumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dupilumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
